Cabometyx® (cabozantinib) – New indication
January 14, 2019 - Exelixis announced the FDA approval of Cabometyx (cabozantinib) tablets, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).
Download PDF
